Alex Polotsky
Concepts (398)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fertilization in Vitro | 16 | 2024 | 108 | 3.350 |
Why?
| | Obesity | 29 | 2024 | 3116 | 3.130 |
Why?
| | Follicle Stimulating Hormone | 14 | 2023 | 266 | 2.920 |
Why?
| | Live Birth | 12 | 2024 | 81 | 2.890 |
Why?
| | Embryo Transfer | 8 | 2024 | 45 | 2.350 |
Why?
| | Luteinizing Hormone | 16 | 2021 | 207 | 2.320 |
Why?
| | Pregnancy Rate | 12 | 2024 | 81 | 2.090 |
Why?
| | Infertility, Female | 11 | 2021 | 122 | 2.040 |
Why?
| | Oocytes | 7 | 2021 | 185 | 1.850 |
Why?
| | Menopause | 7 | 2014 | 326 | 1.840 |
Why?
| | Gonadotropins | 4 | 2023 | 44 | 1.750 |
Why?
| | Ovulation Induction | 9 | 2024 | 65 | 1.490 |
Why?
| | Infertility | 6 | 2018 | 61 | 1.420 |
Why?
| | Pregnancy Outcome | 5 | 2024 | 503 | 1.420 |
Why?
| | Estradiol | 7 | 2024 | 515 | 1.370 |
Why?
| | Oocyte Donation | 2 | 2020 | 6 | 1.270 |
Why?
| | Progesterone | 6 | 2024 | 215 | 1.200 |
Why?
| | Polycystic Ovary Syndrome | 6 | 2018 | 187 | 1.180 |
Why?
| | Reproductive Techniques, Assisted | 4 | 2020 | 47 | 1.180 |
Why?
| | Fertility | 6 | 2019 | 173 | 1.170 |
Why?
| | Aromatase Inhibitors | 4 | 2020 | 78 | 1.140 |
Why?
| | Body Mass Index | 14 | 2024 | 2445 | 1.110 |
Why?
| | Pregnancy | 27 | 2024 | 7202 | 1.070 |
Why?
| | Menstrual Cycle | 5 | 2019 | 145 | 1.050 |
Why?
| | Ovary | 5 | 2022 | 233 | 0.990 |
Why?
| | Sperm Injections, Intracytoplasmic | 5 | 2014 | 15 | 0.970 |
Why?
| | Corpus Luteum | 3 | 2016 | 23 | 0.950 |
Why?
| | Metabolic Syndrome | 5 | 2017 | 360 | 0.950 |
Why?
| | Birth Rate | 3 | 2020 | 31 | 0.930 |
Why?
| | Anti-Mullerian Hormone | 4 | 2022 | 61 | 0.910 |
Why?
| | Weight Gain | 4 | 2016 | 561 | 0.850 |
Why?
| | Female | 79 | 2024 | 78845 | 0.830 |
Why?
| | Women's Health | 6 | 2012 | 314 | 0.810 |
Why?
| | Weight Loss | 6 | 2016 | 858 | 0.800 |
Why?
| | Infertility, Male | 5 | 2017 | 80 | 0.790 |
Why?
| | Cryopreservation | 4 | 2021 | 113 | 0.780 |
Why?
| | Caloric Restriction | 3 | 2014 | 133 | 0.780 |
Why?
| | Hyperandrogenism | 3 | 2017 | 25 | 0.780 |
Why?
| | Obstetrics | 2 | 2018 | 177 | 0.780 |
Why?
| | Oligomenorrhea | 2 | 2014 | 10 | 0.770 |
Why?
| | Gynecology | 2 | 2018 | 181 | 0.760 |
Why?
| | Oocyte Retrieval | 5 | 2021 | 17 | 0.730 |
Why?
| | Adult | 50 | 2024 | 40777 | 0.690 |
Why?
| | Endometrium | 5 | 2018 | 64 | 0.660 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 7 | 0.640 |
Why?
| | Adiposity | 3 | 2015 | 532 | 0.630 |
Why?
| | Humans | 82 | 2024 | 145475 | 0.630 |
Why?
| | Body Weight | 3 | 2015 | 971 | 0.630 |
Why?
| | Granulosa Cells | 2 | 2021 | 36 | 0.620 |
Why?
| | Parity | 2 | 2011 | 111 | 0.620 |
Why?
| | Ovarian Reserve | 1 | 2019 | 18 | 0.600 |
Why?
| | Gestational Sac | 1 | 2019 | 1 | 0.590 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2019 | 20 | 0.580 |
Why?
| | Eicosapentaenoic Acid | 1 | 2019 | 37 | 0.570 |
Why?
| | Pregnancy, Ectopic | 1 | 2019 | 54 | 0.570 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2021 | 1419 | 0.570 |
Why?
| | Injections | 1 | 2019 | 199 | 0.550 |
Why?
| | Docosahexaenoic Acids | 1 | 2019 | 88 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 3 | 2018 | 1371 | 0.540 |
Why?
| | Sperm Motility | 2 | 2017 | 37 | 0.540 |
Why?
| | Teratozoospermia | 1 | 2017 | 3 | 0.530 |
Why?
| | Premenopause | 2 | 2016 | 125 | 0.530 |
Why?
| | Hormones | 2 | 2017 | 135 | 0.530 |
Why?
| | Methotrexate | 1 | 2019 | 233 | 0.530 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 2 | 0.520 |
Why?
| | Biometry | 1 | 2017 | 66 | 0.520 |
Why?
| | Fathers | 1 | 2017 | 53 | 0.510 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2017 | 52 | 0.510 |
Why?
| | Ovulation | 6 | 2018 | 46 | 0.490 |
Why?
| | Overweight | 2 | 2013 | 614 | 0.490 |
Why?
| | Premature Birth | 1 | 2020 | 388 | 0.480 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 196 | 0.480 |
Why?
| | Single Embryo Transfer | 1 | 2016 | 3 | 0.480 |
Why?
| | High Fructose Corn Syrup | 1 | 2015 | 9 | 0.460 |
Why?
| | Ovarian Follicle | 3 | 2021 | 78 | 0.450 |
Why?
| | Dietary Supplements | 2 | 2019 | 583 | 0.440 |
Why?
| | Coitus | 1 | 2015 | 24 | 0.440 |
Why?
| | Logistic Models | 8 | 2016 | 2134 | 0.440 |
Why?
| | Evidence-Based Medicine | 3 | 2014 | 740 | 0.440 |
Why?
| | Blastocyst | 3 | 2020 | 50 | 0.430 |
Why?
| | DNA Damage | 1 | 2017 | 437 | 0.420 |
Why?
| | Embryo Implantation | 4 | 2018 | 34 | 0.420 |
Why?
| | Luteal Phase | 5 | 2014 | 51 | 0.420 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 143 | 0.420 |
Why?
| | Dietary Fats | 2 | 2016 | 308 | 0.410 |
Why?
| | Health | 1 | 2014 | 82 | 0.410 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1327 | 0.410 |
Why?
| | Testosterone | 2 | 2016 | 416 | 0.410 |
Why?
| | Gonadotropin-Releasing Hormone | 5 | 2021 | 217 | 0.400 |
Why?
| | Models, Biological | 4 | 2017 | 1764 | 0.400 |
Why?
| | Cancer Survivors | 1 | 2019 | 337 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.390 |
Why?
| | Adenomyosis | 1 | 2013 | 7 | 0.390 |
Why?
| | Retrospective Studies | 13 | 2024 | 17291 | 0.390 |
Why?
| | Follicle Stimulating Hormone, Human | 2 | 2023 | 14 | 0.380 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2017 | 440 | 0.380 |
Why?
| | Longevity | 2 | 2012 | 178 | 0.380 |
Why?
| | Influenza Vaccines | 1 | 2017 | 534 | 0.380 |
Why?
| | Models, Statistical | 1 | 2017 | 671 | 0.370 |
Why?
| | Fasting | 1 | 2014 | 279 | 0.370 |
Why?
| | Young Adult | 17 | 2021 | 14219 | 0.370 |
Why?
| | Diet, Ketogenic | 1 | 2012 | 39 | 0.360 |
Why?
| | Reproductive Medicine | 1 | 2012 | 18 | 0.360 |
Why?
| | Uterus | 1 | 2013 | 227 | 0.350 |
Why?
| | Influenza, Human | 1 | 2017 | 624 | 0.340 |
Why?
| | Cholesterol, HDL | 1 | 2012 | 201 | 0.340 |
Why?
| | Intra-Abdominal Fat | 1 | 2012 | 101 | 0.340 |
Why?
| | Life Expectancy | 1 | 2012 | 73 | 0.340 |
Why?
| | Cytokines | 2 | 2015 | 2067 | 0.330 |
Why?
| | Nutritional Status | 1 | 2013 | 353 | 0.310 |
Why?
| | MicroRNAs | 2 | 2018 | 686 | 0.310 |
Why?
| | Fallopian Tubes | 3 | 2022 | 33 | 0.310 |
Why?
| | Diet | 1 | 2017 | 1277 | 0.300 |
Why?
| | Odds Ratio | 4 | 2016 | 1082 | 0.300 |
Why?
| | Lithium Chloride | 1 | 2009 | 14 | 0.300 |
Why?
| | Mass Screening | 1 | 2018 | 1360 | 0.290 |
Why?
| | Estrogens | 3 | 2019 | 367 | 0.290 |
Why?
| | Vaccination | 1 | 2017 | 1426 | 0.290 |
Why?
| | Fertility Agents, Female | 2 | 2021 | 23 | 0.280 |
Why?
| | Perception | 1 | 2011 | 378 | 0.280 |
Why?
| | Smoking | 2 | 2015 | 1472 | 0.280 |
Why?
| | Androgens | 3 | 2016 | 181 | 0.280 |
Why?
| | Chorionic Gonadotropin | 1 | 2008 | 78 | 0.280 |
Why?
| | Hormone Antagonists | 2 | 2021 | 33 | 0.270 |
Why?
| | Body Composition | 1 | 2012 | 693 | 0.270 |
Why?
| | Urologic Surgical Procedures, Male | 3 | 2014 | 35 | 0.270 |
Why?
| | Societies, Medical | 1 | 2012 | 899 | 0.260 |
Why?
| | Adolescent | 17 | 2021 | 22530 | 0.260 |
Why?
| | Perimenopause | 3 | 2015 | 69 | 0.260 |
Why?
| | Prospective Studies | 9 | 2023 | 8057 | 0.260 |
Why?
| | RNA, Messenger | 1 | 2015 | 2803 | 0.260 |
Why?
| | Monte Carlo Method | 2 | 2017 | 147 | 0.250 |
Why?
| | Markov Chains | 2 | 2017 | 132 | 0.250 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2017 | 199 | 0.250 |
Why?
| | Follicular Phase | 3 | 2015 | 41 | 0.240 |
Why?
| | Time Factors | 7 | 2017 | 7123 | 0.240 |
Why?
| | United States | 10 | 2021 | 16098 | 0.240 |
Why?
| | Mitochondria | 1 | 2013 | 992 | 0.230 |
Why?
| | Longitudinal Studies | 6 | 2015 | 2953 | 0.230 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 2187 | 0.220 |
Why?
| | Biomarkers | 6 | 2021 | 4295 | 0.220 |
Why?
| | Middle Aged | 19 | 2020 | 36215 | 0.210 |
Why?
| | Animals | 15 | 2021 | 38030 | 0.210 |
Why?
| | Pregnancy Complications | 2 | 2024 | 602 | 0.210 |
Why?
| | Infant, Newborn | 3 | 2024 | 6447 | 0.210 |
Why?
| | Nitriles | 3 | 2015 | 207 | 0.210 |
Why?
| | Diet, High-Fat | 2 | 2016 | 266 | 0.210 |
Why?
| | Risk Factors | 9 | 2017 | 10885 | 0.200 |
Why?
| | Triazoles | 3 | 2015 | 187 | 0.200 |
Why?
| | Reproduction | 3 | 2017 | 208 | 0.200 |
Why?
| | Varicocele | 2 | 2014 | 12 | 0.190 |
Why?
| | Blood Glucose | 2 | 2017 | 2341 | 0.190 |
Why?
| | Patient Selection | 2 | 2021 | 738 | 0.190 |
Why?
| | Computer Simulation | 2 | 2017 | 1003 | 0.190 |
Why?
| | Leiomyoma | 2 | 2017 | 61 | 0.190 |
Why?
| | Epithelial Cells | 1 | 2009 | 1131 | 0.190 |
Why?
| | Obesity, Morbid | 1 | 2007 | 293 | 0.180 |
Why?
| | Uterine Neoplasms | 2 | 2017 | 98 | 0.180 |
Why?
| | Cesarean Section | 1 | 2024 | 230 | 0.180 |
Why?
| | Ultrasonography | 2 | 2018 | 785 | 0.180 |
Why?
| | Cell Nucleolus | 2 | 2012 | 20 | 0.180 |
Why?
| | Hypothalamus | 2 | 2014 | 163 | 0.170 |
Why?
| | Research Subjects | 1 | 2021 | 41 | 0.170 |
Why?
| | Endometriosis | 1 | 2021 | 58 | 0.160 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 265 | 0.160 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 19 | 0.160 |
Why?
| | Fertility Preservation | 1 | 2021 | 55 | 0.160 |
Why?
| | Prevalence | 4 | 2012 | 2865 | 0.160 |
Why?
| | Multivariate Analysis | 4 | 2013 | 1547 | 0.160 |
Why?
| | Treatment Outcome | 6 | 2021 | 11772 | 0.150 |
Why?
| | Abortion, Spontaneous | 2 | 2017 | 118 | 0.150 |
Why?
| | Cross-Sectional Studies | 7 | 2018 | 5905 | 0.150 |
Why?
| | Male | 16 | 2018 | 72843 | 0.150 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1923 | 0.140 |
Why?
| | Hysterosalpingography | 1 | 2018 | 9 | 0.140 |
Why?
| | Progestins | 1 | 2019 | 66 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1217 | 0.140 |
Why?
| | Bayes Theorem | 2 | 2017 | 420 | 0.140 |
Why?
| | Environmental Health | 1 | 2018 | 40 | 0.130 |
Why?
| | Phthalic Acids | 1 | 2018 | 42 | 0.130 |
Why?
| | Endocrine Disruptors | 1 | 2018 | 41 | 0.130 |
Why?
| | Hypogonadism | 2 | 2015 | 93 | 0.130 |
Why?
| | Puberty | 1 | 2019 | 137 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2019 | 165 | 0.130 |
Why?
| | Biostatistics | 1 | 2017 | 19 | 0.130 |
Why?
| | Genetic Testing | 1 | 2020 | 480 | 0.130 |
Why?
| | Fertility Agents | 1 | 2017 | 3 | 0.130 |
Why?
| | Sweating | 2 | 2014 | 43 | 0.130 |
Why?
| | Insemination, Artificial | 1 | 2017 | 12 | 0.130 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 73 | 0.130 |
Why?
| | Likelihood Functions | 1 | 2017 | 138 | 0.120 |
Why?
| | Ultrasonography, Prenatal | 1 | 2019 | 295 | 0.120 |
Why?
| | Embryonic Development | 1 | 2017 | 125 | 0.120 |
Why?
| | Aromatase | 2 | 2014 | 35 | 0.120 |
Why?
| | NF-kappa B | 1 | 2020 | 666 | 0.120 |
Why?
| | Hot Flashes | 2 | 2014 | 91 | 0.120 |
Why?
| | Ovarian Diseases | 1 | 2016 | 14 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 159 | 0.120 |
Why?
| | Maternal Exposure | 1 | 2018 | 189 | 0.120 |
Why?
| | Chronic Disease | 2 | 2014 | 1808 | 0.120 |
Why?
| | Maternal Age | 1 | 2016 | 128 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2018 | 910 | 0.110 |
Why?
| | Transcriptome | 2 | 2021 | 1038 | 0.110 |
Why?
| | Hydrocortisone | 1 | 2017 | 298 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 127 | 0.110 |
Why?
| | Clomiphene | 1 | 2015 | 16 | 0.110 |
Why?
| | Incidence | 2 | 2014 | 2923 | 0.110 |
Why?
| | Cumulus Cells | 1 | 2015 | 7 | 0.110 |
Why?
| | Anovulation | 1 | 2015 | 9 | 0.110 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 105 | 0.110 |
Why?
| | Data Interpretation, Statistical | 1 | 2017 | 368 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2015 | 2507 | 0.110 |
Why?
| | Waist Circumference | 2 | 2017 | 143 | 0.110 |
Why?
| | Circadian Rhythm | 2 | 2017 | 512 | 0.110 |
Why?
| | Obesity, Abdominal | 1 | 2014 | 47 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1356 | 0.110 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 277 | 0.110 |
Why?
| | Adiponectin | 1 | 2016 | 241 | 0.100 |
Why?
| | Neoplasms | 2 | 2021 | 2906 | 0.100 |
Why?
| | Insurance Coverage | 1 | 2016 | 244 | 0.100 |
Why?
| | Phospholipids | 1 | 2015 | 214 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2015 | 389 | 0.100 |
Why?
| | Hysteroscopy | 1 | 2013 | 14 | 0.100 |
Why?
| | Pulsatile Flow | 2 | 2011 | 61 | 0.100 |
Why?
| | Reproductive Health | 1 | 2014 | 91 | 0.100 |
Why?
| | Insurance, Health | 1 | 2016 | 310 | 0.100 |
Why?
| | Ketone Bodies | 1 | 2012 | 16 | 0.090 |
Why?
| | DNA Methylation | 1 | 2018 | 674 | 0.090 |
Why?
| | Triglycerides | 2 | 2017 | 520 | 0.090 |
Why?
| | Birth Weight | 1 | 2016 | 514 | 0.090 |
Why?
| | Cohort Studies | 4 | 2012 | 6013 | 0.090 |
Why?
| | Fatty Acids | 1 | 2015 | 457 | 0.090 |
Why?
| | Organizational Objectives | 1 | 2012 | 67 | 0.090 |
Why?
| | Interinstitutional Relations | 1 | 2012 | 55 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 1193 | 0.090 |
Why?
| | Body Height | 1 | 2013 | 202 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2017 | 3623 | 0.090 |
Why?
| | Education, Continuing | 1 | 2012 | 42 | 0.090 |
Why?
| | Hyperthyroidism | 1 | 2012 | 22 | 0.090 |
Why?
| | Cell Cycle | 1 | 2015 | 598 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1767 | 0.090 |
Why?
| | Japan | 1 | 2011 | 149 | 0.080 |
Why?
| | Algorithms | 2 | 2017 | 1845 | 0.080 |
Why?
| | Placenta | 1 | 2018 | 786 | 0.080 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2011 | 43 | 0.080 |
Why?
| | New York | 1 | 2011 | 128 | 0.080 |
Why?
| | China | 1 | 2011 | 270 | 0.080 |
Why?
| | Mice | 4 | 2021 | 18329 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2012 | 223 | 0.080 |
Why?
| | Glycolysis | 1 | 2012 | 340 | 0.080 |
Why?
| | Quality of Life | 2 | 2014 | 3204 | 0.080 |
Why?
| | Body Fat Distribution | 1 | 2010 | 46 | 0.080 |
Why?
| | Research Design | 2 | 2014 | 1137 | 0.080 |
Why?
| | Ovariectomy | 1 | 2011 | 166 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 527 | 0.080 |
Why?
| | Pituitary Gland | 1 | 2011 | 149 | 0.080 |
Why?
| | Abdominal Fat | 1 | 2010 | 51 | 0.080 |
Why?
| | Information Dissemination | 1 | 2012 | 224 | 0.080 |
Why?
| | Databases, Factual | 1 | 2016 | 1490 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 412 | 0.080 |
Why?
| | Spermatozoa | 1 | 2010 | 106 | 0.080 |
Why?
| | Acculturation | 1 | 2010 | 55 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2009 | 64 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 74 | 0.070 |
Why?
| | Luteal Cells | 1 | 2008 | 3 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 83 | 0.070 |
Why?
| | Self Report | 1 | 2013 | 870 | 0.070 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 170 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1300 | 0.070 |
Why?
| | Cholesterol | 1 | 2010 | 408 | 0.070 |
Why?
| | Nuclear Pore | 1 | 2008 | 19 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 392 | 0.070 |
Why?
| | Bariatric Surgery | 2 | 2009 | 252 | 0.070 |
Why?
| | Thyroid Neoplasms | 1 | 2012 | 350 | 0.070 |
Why?
| | Siblings | 1 | 2008 | 196 | 0.070 |
Why?
| | Epilepsy | 1 | 2012 | 390 | 0.070 |
Why?
| | Patient Compliance | 1 | 2012 | 587 | 0.070 |
Why?
| | Energy Intake | 1 | 2010 | 512 | 0.060 |
Why?
| | Hysterectomy | 1 | 2008 | 138 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4560 | 0.060 |
Why?
| | Signal Transduction | 1 | 2020 | 5216 | 0.060 |
Why?
| | Fever | 1 | 2008 | 319 | 0.060 |
Why?
| | Cuba | 3 | 2010 | 15 | 0.060 |
Why?
| | Central America | 3 | 2010 | 28 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2597 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1210 | 0.060 |
Why?
| | South America | 3 | 2010 | 56 | 0.060 |
Why?
| | Puerto Rico | 3 | 2010 | 62 | 0.060 |
Why?
| | Metabolome | 1 | 2009 | 388 | 0.060 |
Why?
| | Metformin | 1 | 2009 | 329 | 0.060 |
Why?
| | Lipids | 1 | 2010 | 707 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2930 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1747 | 0.050 |
Why?
| | Diabetes Mellitus | 2 | 2010 | 1097 | 0.050 |
Why?
| | Hypertension | 2 | 2010 | 1273 | 0.050 |
Why?
| | Stroke | 1 | 2014 | 1270 | 0.050 |
Why?
| | Risk Assessment | 2 | 2011 | 3747 | 0.050 |
Why?
| | Energy Metabolism | 1 | 2010 | 935 | 0.050 |
Why?
| | Recovery of Function | 1 | 2008 | 716 | 0.050 |
Why?
| | Inflammation | 1 | 2015 | 2878 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2121 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1508 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2021 | 2062 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 32 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 7 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 6 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 20 | 0.040 |
Why?
| | Aging | 1 | 2012 | 1969 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 130 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 665 | 0.040 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2020 | 50 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3904 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 244 | 0.040 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2020 | 23 | 0.040 |
Why?
| | Dominican Republic | 2 | 2010 | 28 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2020 | 113 | 0.040 |
Why?
| | I-kappa B Proteins | 1 | 2020 | 75 | 0.040 |
Why?
| | Choice Behavior | 1 | 2021 | 180 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 756 | 0.040 |
Why?
| | Prostheses and Implants | 1 | 2021 | 137 | 0.040 |
Why?
| | Child | 1 | 2019 | 22707 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 471 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 452 | 0.030 |
Why?
| | Exercise | 1 | 2010 | 2198 | 0.030 |
Why?
| | Ovum | 1 | 2018 | 30 | 0.030 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 2018 | 139 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2018 | 247 | 0.030 |
Why?
| | Pregnancy Tests | 1 | 2017 | 11 | 0.030 |
Why?
| | Hirsutism | 1 | 2017 | 12 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1707 | 0.030 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 45 | 0.030 |
Why?
| | Litter Size | 1 | 2016 | 18 | 0.030 |
Why?
| | Pituitary-Adrenal System | 1 | 2017 | 164 | 0.030 |
Why?
| | Mice, Obese | 1 | 2016 | 68 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 393 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2823 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2970 | 0.030 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 66 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 192 | 0.030 |
Why?
| | Lipoproteins, HDL | 1 | 2015 | 100 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 93 | 0.030 |
Why?
| | Embryo Disposition | 1 | 2014 | 1 | 0.030 |
Why?
| | Zygote Intrafallopian Transfer | 1 | 2014 | 2 | 0.030 |
Why?
| | Cleavage Stage, Ovum | 1 | 2014 | 6 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 337 | 0.030 |
Why?
| | Estrone | 1 | 2014 | 41 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1044 | 0.030 |
Why?
| | Laparoscopy | 1 | 2018 | 481 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2015 | 500 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2016 | 891 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 679 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2021 | 1196 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 749 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 428 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 536 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 357 | 0.020 |
Why?
| | Thyrotropin | 1 | 2012 | 120 | 0.020 |
Why?
| | Thyroidectomy | 1 | 2012 | 92 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1476 | 0.020 |
Why?
| | Sperm Count | 1 | 2010 | 22 | 0.020 |
Why?
| | Vaginal Diseases | 1 | 2010 | 19 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2018 | 4148 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 3 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3413 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 6066 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1082 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 782 | 0.020 |
Why?
| | Pregnanediol | 1 | 2008 | 23 | 0.020 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2008 | 7 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3155 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2017 | 1244 | 0.020 |
Why?
| | Survivors | 1 | 2012 | 523 | 0.020 |
Why?
| | Papio | 1 | 2008 | 70 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 360 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2008 | 67 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 466 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1001 | 0.020 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2010 | 195 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 365 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3342 | 0.020 |
Why?
| | Cause of Death | 1 | 2009 | 470 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2009 | 608 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2010 | 314 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2009 | 529 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1323 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5983 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1997 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4554 | 0.010 |
Why?
| | Anxiety | 1 | 2010 | 1118 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2010 | 1146 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1505 | 0.010 |
Why?
| | Depression | 1 | 2010 | 1546 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5423 | 0.010 |
Why?
| | Aged | 1 | 2009 | 26153 | 0.000 |
Why?
|
|
Polotsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|